VCYT
Veracyte, Inc. · Healthcare · Medical - Diagnostics & Research
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 117 | +3 | 67.53M | $3.96B | +9 | −7 |
| Q1 2026 | 118 | +6 | 67.37M | $2.17B | +10 | −4 |
| Q4 2025 | 112 | 0 | 69.04M | $2.91B | +2 | −2 |
| Q3 2025 | 18 | -2 | 46.98M | $1.61B | — | −3 |
| Q2 2025 | 18 | 0 | 39.06M | $1.06B | +1 | −1 |
| Q1 2025 | 15 | -1 | 15.53M | $460.45M | — | −1 |
| Q4 2024 | 16 | +1 | 17.75M | $702.81M | +1 | — |
| Q3 2024 | 14 | +1 | 14.22M | $484.20M | +3 | −2 |
| Q2 2024 | 13 | — | 18.04M | $390.85M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 6.88M | — | $149.01M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 2 | ARK Investment Management ✦ | 6.81M | — | $147.56M | 1.3% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.83M | — | $39.59M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Fisher Asset Management ✦ | 889.81K | — | $19.28M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Point72 Asset Management ✦ | 566.63K | — | $12.28M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 420.80K | — | $9.12M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Duquesne Family Office ✦ | 259.94K | — | $5.63M | 0.2% | n/c | 1 | SEC ↗ |
| 8 | Norges Bank ✦ (passive) | 156.40K | — | $3.39M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Millennium Management ✦ | 64.23K | — | $1.39M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 58.42K | — | $1.27M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 11 | Citadel Advisors ✦ | 47.64K | — | $1.03M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 44.70K | — | $969,000 | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Gotham Asset Management ✦ | 15.06K | — | $326,350 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 333 holders, 87.61M shares, $2.75B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 4.01K sh · $160,600
Director · 5.00K sh · $204,747
Officer · 1.10K sh · $48,039
Officer · 2.48K sh · $106,030
Officer · 1.18K sh · $51,364
Officer · 2.71K sh · $118,105
Officer · 10.40K sh · $446,305
Officer · 2.15K sh · $92,173
Director · 1.86K sh · $80,096
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology